Skip to main content
Top
Published in: Journal of Hepato-Biliary-Pancreatic Sciences 3/2013

Open Access 01-03-2013 | Original article

Factors predicting survival after post-transplant hepatocellular carcinoma recurrence

Authors: Christian Toso, Sonia Cader, Ariane Mentha-Dugerdil, Glenda Meeberg, Pietro Majno, Isabelle Morard, Emiliano Giostra, Thierry Berney, Philippe Morel, Gilles Mentha, Norman M. Kneteman

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 3/2013

Login to get access

Abstract

Background

Although factors associated with an increased risk of recurrence after liver transplantation for hepatocellular carcinoma (HCC) have been extensively studied, the history of patients with a post-transplant recurrence is poorly known.

Methods

Patients experiencing a post-transplant HCC recurrence from 1996 to 2011 in two transplant programs were included. Demographic, transplant, and post-recurrence variables were assessed.

Results

Thirty patients experienced an HCC recurrence–22 men and 8 women with a mean age of 55 ± 6 years. Sixteen (53 %) were outside the Milan criteria at the time of transplantation. Most recurrences (60 %) appeared within the first 18 months after transplantation, ranging between 1.7 and 109 months (median 14.2 months). Mean post-recurrence survival was 33 ± 31 months. On univariate analysis, total tumor volume (TTV; p = 0.047), microvascular invasion (p = 0.011), and time from transplant to recurrence (p = 0.001) predicted post-recurrence survival. On multivariate analysis, both time from transplant to recurrence (p = 0.001) and history of rejection (p = 0.043), but not the location of the recurrence or the type of recurrence treatment, predicted post-recurrence survival.

Conclusion

This study suggests that patients with early post-transplant HCC recurrence have worse outcomes. Those with a history of graft rejection have better survivals, possibly due to more active anti-cancer immunity.
Literature
1.
go back to reference Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.PubMedCrossRef Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.PubMedCrossRef
2.
go back to reference Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49(3):832–8.PubMedCrossRef Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49(3):832–8.PubMedCrossRef
3.
go back to reference Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.PubMedCrossRef Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.PubMedCrossRef
4.
go back to reference Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14(8):1107–15.PubMedCrossRef Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14(8):1107–15.PubMedCrossRef
5.
go back to reference Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–9.PubMedCrossRef Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–9.PubMedCrossRef
6.
go back to reference Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83(9):1162–8.PubMedCrossRef Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83(9):1162–8.PubMedCrossRef
7.
go back to reference Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010;51(4):1237–43.PubMedCrossRef Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010;51(4):1237–43.PubMedCrossRef
8.
go back to reference Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011;10:2031–5.CrossRef Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011;10:2031–5.CrossRef
9.
go back to reference Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, et al. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. 2010;17(9):2283–9.PubMedCrossRef Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, et al. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. 2010;17(9):2283–9.PubMedCrossRef
10.
go back to reference Kornberg A, Kupper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol. 2010;36(3):275–80.PubMedCrossRef Kornberg A, Kupper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol. 2010;36(3):275–80.PubMedCrossRef
11.
go back to reference Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi NJ, et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2010;16(5):678–84.PubMedCrossRef Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi NJ, et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2010;16(5):678–84.PubMedCrossRef
12.
go back to reference Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc. 2010;42(2):660–2.PubMedCrossRef Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc. 2010;42(2):660–2.PubMedCrossRef
13.
go back to reference Davis E, Wiesner R, Valdecasas J, Kita Y, Rossi M, Schwartz M. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2011;17(Suppl 2):S162–6.PubMedCrossRef Davis E, Wiesner R, Valdecasas J, Kita Y, Rossi M, Schwartz M. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2011;17(Suppl 2):S162–6.PubMedCrossRef
14.
go back to reference Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137(10):1445–53.PubMedCrossRef Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137(10):1445–53.PubMedCrossRef
15.
go back to reference Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol. 2006;12(45):7319–25.PubMed Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol. 2006;12(45):7319–25.PubMed
16.
go back to reference Vivarelli M, Cucchetti A, La BG, Ravaioli M, Del GM, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248(5):857–62.PubMedCrossRef Vivarelli M, Cucchetti A, La BG, Ravaioli M, Del GM, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248(5):857–62.PubMedCrossRef
17.
go back to reference Marangoni G, Faraj W, Sethi H, Rela M, Muiesan P, Heaton N. Liver resection in liver transplant recipients. Hepatobiliary Pancreat Dis Int. 2008;7(6):590–4.PubMed Marangoni G, Faraj W, Sethi H, Rela M, Muiesan P, Heaton N. Liver resection in liver transplant recipients. Hepatobiliary Pancreat Dis Int. 2008;7(6):590–4.PubMed
18.
go back to reference Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg. 1998;5(1):29–34.PubMedCrossRef Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg. 1998;5(1):29–34.PubMedCrossRef
19.
go back to reference Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–22.PubMedCrossRef Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–22.PubMedCrossRef
20.
go back to reference Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. 2010;10:190.PubMedCrossRef Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. 2010;10:190.PubMedCrossRef
21.
go back to reference Koh WP, Robien K, Wang R, Govindarajan S, Yuan JM, Yu MC. Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study. Br J Cancer. 2011;105(9):1430–5.PubMedCrossRef Koh WP, Robien K, Wang R, Govindarajan S, Yuan JM, Yu MC. Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study. Br J Cancer. 2011;105(9):1430–5.PubMedCrossRef
22.
go back to reference McCleary NJ, Niedzwiecki D, Hollis D, Saltz LB, Schaefer P, Whittom R, et al. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer. 2010;116(4):957–66.PubMedCrossRef McCleary NJ, Niedzwiecki D, Hollis D, Saltz LB, Schaefer P, Whittom R, et al. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer. 2010;116(4):957–66.PubMedCrossRef
23.
go back to reference Wei PL, Kuo LJ, Huang MT, Ting WC, Ho YS, Wang W, et al. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann Surg Oncol. 2011;18(6):1782–90.PubMedCrossRef Wei PL, Kuo LJ, Huang MT, Ting WC, Ho YS, Wang W, et al. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann Surg Oncol. 2011;18(6):1782–90.PubMedCrossRef
Metadata
Title
Factors predicting survival after post-transplant hepatocellular carcinoma recurrence
Authors
Christian Toso
Sonia Cader
Ariane Mentha-Dugerdil
Glenda Meeberg
Pietro Majno
Isabelle Morard
Emiliano Giostra
Thierry Berney
Philippe Morel
Gilles Mentha
Norman M. Kneteman
Publication date
01-03-2013
Publisher
Springer Japan
Published in
Journal of Hepato-Biliary-Pancreatic Sciences / Issue 3/2013
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-012-0528-4

Other articles of this Issue 3/2013

Journal of Hepato-Biliary-Pancreatic Sciences 3/2013 Go to the issue